Genflow sees sustained safety and efficacy in SIRT6 beagle trial

Genflow Biosciences Plc ( (GB:GENF) ) just unveiled an update.

Genflow Biosciences reported that three-month follow-up data from its SLAB trial in aged beagles show sustained safety and efficacy of its SIRT6 centenarian gene therapy, with no adverse events and maintained improvements across multiple functional endpoints. The ongoing study, which runs until late July 2026 and includes deeper analyses such as methylation clock and muscle histology, reinforces management’s view that its SIRT6 platform could offer a disease-modifying approach to age-related decline in companion animals and underpins active discussions with potential animal health partners on licensing, co-development and commercialisation opportunities.

The most recent analyst rating on (GB:GENF) stock is a Hold with a £2.00 price target. To see the full list of analyst forecasts on Genflow Biosciences Plc stock, see the GB:GENF Stock Forecast page.

Spark’s Take on GENF Stock

According to Spark, TipRanks’ AI Analyst, GENF is a Neutral.

The score is primarily constrained by weak financial performance (no revenue, ongoing losses, continued cash burn) and a weakened balance sheet with negative equity. Technicals are moderately supportive given the price trend above key moving averages, but valuation remains pressured due to losses and no dividend support.

To see Spark’s full report on GENF stock, click here.

More about Genflow Biosciences Plc

Genflow Biosciences Plc is a UK-headquartered biotechnology company with R&D operations in Belgium, developing gene therapies targeting age-related diseases. Its lead candidate, GF-1002, delivers a centenarian variant of the SIRT6 gene and is being tested in aged dogs, with additional programmes exploring its potential in conditions such as MASH, a prevalent chronic liver disease lacking effective treatments.

Average Trading Volume: 2,329,809

Technical Sentiment Signal: Buy

Current Market Cap: £10.45M

For detailed information about GENF stock, go to TipRanks’ Stock Analysis page.